{"disease":{"id":"neoadjuvant-chemoimmunotherapy","name":"neoadjuvant chemoimmunotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06288373","title":"Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07528066","title":"Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT05925751","title":"Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT06056336","title":"Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":73,"lead_sponsor_name":"Guo Xufeng","has_results":false},{"nct_id":"NCT07137858","title":"Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07127497","title":"Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital of Anhui Medical University","has_results":false},{"nct_id":"NCT06289751","title":"Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07165847","title":"Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT06288360","title":"Neoadjuvant Immunochemotherapy in PD-L1-negative LACC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06289062","title":"Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06436040","title":"Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT07478900","title":"Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"All India Institute of Medical Sciences, Bhubaneswar","has_results":false},{"nct_id":"NCT07092449","title":"Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT07145931","title":"Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Sun Yat-sen University","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}